---
layout: default
title: Clavulanic Acid
parent: 僅模型預測 (L5)
nav_order: 127
evidence_level: L5
indication_count: 10
---

# Clavulanic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Clavulanic Acid: From β-Lactamase Inhibitor (Combination Antibiotic) to Ureaplasma Urethritis

## One-Sentence Summary

Clavulanic acid is a β-lactamase inhibitor with no standalone registered indications; it is used exclusively in fixed-dose combinations such as amoxicillin-clavulanate (Augmentin) to protect β-lactam antibiotics from enzymatic degradation.
The TxGNN model predicts it may be effective for **Ureaplasma Urethritis**, with **0 clinical trials** and **0 supporting publications** currently available for this indication.
Critically, the mechanistic rationale for this prediction is absent — *Ureaplasma* species lack cell walls and are inherently resistant to β-lactam antibiotics — making this an **L5 model-only prediction** that warrants a **Hold** decision.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No standalone registered indication (used exclusively in combination with β-lactam antibiotics) |
| Predicted New Indication | Ureaplasma Urethritis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Clavulanic acid is a suicide inhibitor of bacterial β-lactamase enzymes, derived from *Streptomyces clavuligerus*. Its mechanism works by binding irreversibly to the β-lactamase active site, preventing the enzyme from inactivating co-administered β-lactam antibiotics such as amoxicillin. On its own, clavulanic acid has negligible direct antibacterial activity — it is purely an adjuvant that restores efficacy to partner antibiotics against resistant organisms.

For this mechanism to be clinically relevant, the target pathogen must (a) produce β-lactamase enzymes, and (b) possess a cell wall susceptible to β-lactam attack. *Ureaplasma urealyticum*, the causative organism in Ureaplasma urethritis, satisfies neither condition. It is a wall-less bacterium of the class Mollicutes and is therefore **inherently and completely resistant** to all β-lactam antibiotics regardless of β-lactamase inhibitor co-administration. There is no mechanistic pathway — enzymatic, structural, or pharmacological — by which clavulanic acid could exert a therapeutic effect against *Ureaplasma*. Standard of care remains doxycycline or azithromycin.

The high TxGNN prediction score (99.93%) most likely reflects indirect knowledge graph associations — for example, connections between clavulanic acid-containing combinations and urinary tract infection nodes generally — rather than a genuine drug-disease biological relationship. This case illustrates a critical limitation of graph embedding models: a high confidence score can arise from network proximity without any mechanistic plausibility. All 10 predicted indications in this evidence pack share the same fundamental problem: clavulanic acid has no standalone therapeutic activity, and the AI model appears to be inheriting associations from its combination partner (amoxicillin) rather than evaluating the isolated compound.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Clavulanic acid in Ureaplasma Urethritis.

---

## Literature Evidence

Currently no related literature available for Clavulanic acid in Ureaplasma Urethritis.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Every one of the 10 TxGNN-predicted indications lacks direct mechanistic support for clavulanic acid as a standalone agent; the top prediction (Ureaplasma urethritis) is mechanistically invalid, and the remaining predictions (including Pelvic Inflammatory Disease and broad ligament disease) at best reflect properties of the amoxicillin-clavulanate *combination*, not clavulanic acid alone. With zero supporting clinical trials or literature across all predicted indications, and no SAHPRA registration or South African market presence, there is insufficient basis to proceed.

**To proceed, the following is needed:**

- **Clarify the repurposing scope**: Determine whether the intended research question concerns clavulanic acid as a **standalone agent** or as part of a **fixed-dose combination** (e.g., amoxicillin-clavulanate); these are fundamentally different pharmacological entities for the purposes of drug repurposing analysis
- **Re-run TxGNN using the combination entity**: If the goal is to identify new indications for amoxicillin-clavulanate as a combination product, the TxGNN analysis should be repeated using the combination drug node, which is likely to yield more mechanistically coherent predictions
- **Obtain MOA data from DrugBank** (ID: DB00766) to formally document the mechanism and confirm the limitations identified in this analysis
- **Obtain SAHPRA Professional Information (PI)**: Download and parse the PI to populate safety warnings, contraindications, and drug interaction data currently marked as unavailable
- **Explore novel mechanisms independently**: If there is scientific interest in clavulanic acid beyond β-lactamase inhibition (e.g., emerging research on BlaC inhibition in *Mycobacterium tuberculosis*), this should be assessed via a dedicated literature search and expert pharmacology review, separate from the current TxGNN pipeline

> ⚠️ **YMYL Disclaimer**: This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. Data cutoff: 2026-04-05.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

